SCHEMBL12437612

SCHEMBL12437612

CCN(CCCNC(=O)c1cccc(OC2CCN(CC(c3ccccc3)c3ccccc3)CC2)c1)Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
SLC5A7 Q9GZV3 1/20 0.59
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
SIGMAR1 Q99720 2/20 0.49
CCR3 P51677 2/20 0.48
APP P05067 2/20 0.48
OPRM1 P35372 2/20 0.47
OPRD1 P41143 2/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
OPRK1 P41145 1/20 0.47
LMNA P02545 1/20 0.46
ACKR3 P25106 1/20 0.45
TMEM97 Q5BJF2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437429 0.94 MEN1 (0.63) MEN1KMT2ASLC5A7NPC1RAB9A
SCHEMBL12437566 0.91 MEN1 (0.52) MEN1KMT2ASLC5A7NPC1RAB9A
SCHEMBL12437595 0.91 OPRM1 (0.58) MEN1KMT2ASLC5A7NPC1RAB9A
SCHEMBL12437613 0.90 MEN1 (0.62) MEN1KMT2ASLC5A7NPC1RAB9A
SCHEMBL12437386 0.90 MEN1 (0.64) MEN1KMT2ASLC5A7NPC1RAB9A
SCHEMBL12437728 0.87 APP (0.48) MEN1KMT2ASLC5A7SIGMAR1APP
SCHEMBL12437369 0.86 MEN1 (0.51) MEN1KMT2ASLC5A7NPC1RAB9A
SCHEMBL12437428 0.85 MEN1 (0.66) MEN1KMT2ASLC5A7NPC1RAB9A
SCHEMBL12437523 0.85 OPRM1 (0.57) MEN1KMT2ASLC5A7NPC1RAB9A
SCHEMBL12437767 0.83 USP7 (0.44) MEN1KMT2ASLC5A7SIGMAR1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
WO-2007098086-A2 HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF AVALON PHARMACEUTICALS (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD MEN1 3974/4885KMT2A 2446/4885SLC5A7 4329/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD MEN1 3974/4885KMT2A 2446/4885SLC5A7 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.